期刊论文

Hsu, Yi-Te

英文

Journal of Lipid Research

0022-2275

2011

52

2

278-288

10.1194/jlr.M012161

National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-40932, AG-16583]; Office of Research and Development, US Department of Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040932, R01NS040932, R01NS040932, R01NS040932, R01NS040932] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583, R01AG016583] Funding Source: NIH RePORTER

本校为其他机构

C6-pyridinium (d-erythro-2-N-[6′-(1′′-pyridinium)-hexanoyl]sphingosine bromide [LCL29]) is a cationic mitochondrion-targeting ceramide analog that promotes mitochondrial permeabilization and cancer cell death. In this study, we compared the biological effects of that compound with those of d-erythro-C6-ceramide, its non-mitochondrion-targeting analog. In MCF7 cells it was found that C6-pyridinium ceramide preferentially promoted autophagosome formation and retarded cell growth more extensively than its uncharged analog. This preferential inh...